Obesity and Metabolic Dysfunction-Associated Steatohepatitis

Obesity and MASH: What You Should Know

The number on your scale could increase your odds of developing this advanced liver disease. Here’s how to lower your risk.
Obesity and MASH: What You Should Know
iStock
Obesity can increase your risk of all kinds of health conditions, from type 2 diabetes and heart disease to problems with fertility and sexual function. One such condition you might not be as familiar with is metabolic dysfunction–associated steatohepatitis (MASH), which is a severe form of liver disease.

Keep reading to learn about the link between obesity and MASH and how to reduce your risk of this disease.

What Is MASH?

“MASH is a dysfunction of the liver caused by excess fat cells,” says Mir Ali, MD, a general surgeon and the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA.

Excess fat in the liver is known as steatotic liver disease (SLD) in the medical field. There are several types of SLD. The most common one, metabolic dysfunction-associated steatotic liver disease (MASLD), is related to abnormal metabolism. MASH is an advanced stage of MASLD. “That fatty deposition affects liver function and leads to inflammation of the liver,” says Dr. Ali. And chronic inflammation causes damage that has the potential to progress to fibrosis (scar tissue, which can affect liver function), cirrhosis, liver failure, or other complications, including liver cancer. A liver transplant may be required in advanced liver disease stemming from MASH.

Although alcohol use can lead to chronic liver disease, MASLD and MASH are not related to alcohol consumption. In fact, until recently, they were known as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

An estimated 25 percent of adults in the United States have MASLD. Of those, 20 percent have MASH.

 But these numbers are growing: More than half of the adult population is expected to have MASLD by 2040.

How Having Obesity Increases Your Risk of MASH

Obesity is one of the leading causes of MASLD and MASH. About 75 percent of people with overweight and 90 percent of people with severe obesity develop MASH.

“When [you have] overweight, your body tends to deposit fat all over the place, but it can deposit it in the liver as well,” Ali explains.
Additionally, several other conditions that commonly occur alongside obesity — type 2 diabetes, high cholesterol, and metabolic syndrome — all increase your risk of developing MASH.

Other Risk Factors for MASH

Outside of obesity, other risk factors for developing MASH include:

  • Diabetes or insulin resistance
  • High blood pressure
  • High cholesterol
  • Metabolic syndrome
  • Polycystic ovary syndrome
  • Underactive pituitary gland
  • Underactive thyroid
You may also be at an increased risk of MASH if you’re:

  • Over age 40
  • Postmenopausal
  • Asian or Latino (Asians are also considered to have overweight or obesity at a lower body mass index than the rest of the population)

Symptoms and Diagnosis of MASH

As far as physical symptoms, MASH can present as mild pain on the right side of the abdomen (where the liver is located) or general fatigue, says Ali. But more often than not, people don’t experience symptoms at all — or at least none that can easily be directly attributed to liver disease.

“Most patients don’t even realize they have it,” Ali says. “The liver doesn’t make itself known until it’s progressed beyond mild inflammation. If someone’s experiencing symptoms, their MASH tends to be advancing.”

For this reason, the first signs of MASH usually show up on routine blood work that you might get during an annual physical or as part of an ER visit. It’s called a comprehensive metabolic panel, which includes liver enzymes. “If results are abnormal, it usually warrants further investigation,” he explains.

From there, your doctor may order imaging studies, such as an ultrasound, CT scan, or MRI scan, which can uncover some liver changes. For a definitive diagnosis, a biopsy used to be done. Now, newer, noninvasive tests, such as a FibroScan or blood-based biomarker test, are often used instead.

Why Regular Screening Is Important

Waiting to screen for MASH until symptoms appear isn’t the best strategy, as symptoms often don’t occur until the disease is severe, says Ali. Make sure you see your doctor for regular checkups, and ask for routine lab work that includes a liver function test, so you can catch liver disease before it advances to more serious complications.

“The liver is one of the few organs that can actually regenerate, but with chronic inflammation, it tries to heal, and you end up with more scar [tissue] or fibrosis in the liver,” says Ali. That can progress to cirrhosis, liver failure, or occasionally — but rarely — liver cancer. Other possible complications of MASH that has progressed to cirrhosis include fluid buildup in the abdomen, internal bleeding, an enlarged spleen, kidney failure, brain disorders, and coma.

Once liver damage worsens to cirrhosis, each complication needs to be treated individually. The only option for a cure is a liver transplant, says Ali. “It’s important to make a MASH diagnosis early on to address the causes of it and treat it,” he says.

How to Reduce Your Risk of MASH

If you have overweight or obesity, losing weight should be a priority to reduce your risk of MASH. Trimming 3 to 5 percent of your body weight may be enough to reduce fat in the liver. If you want to improve MASH, losing more than 5 percent is recommended. For liver fibrosis improvement, that number increases to 7 to 10 percent or more.

Here are some additional tips to help you achieve lasting weight loss and lower your MASH risk.

  • Eat a Mediterranean diet. This eating plan emphasizes fresh produce; lean proteins, such as fish and poultry; and omega-3 fatty acids from foods such as nuts and olive oil. The diet is also considered heart healthy, Ali notes.
  • Stay active. Aim for 150 minutes of moderate-intensity aerobic exercise or 75 minutes of vigorous activity, such as cycling or jogging, spread throughout the week. Brisk walking counts, so get outside! You should also try to supplement aerobic activity with two days of resistance training a week.

  • Consider medication. “GLP-1 medications are effective for weight loss, but if cost or supply are an issue, other medications that are a little bit older may be used instead,” says Ali. For example, topiramate, phentermine, or Xenical could be a good fit, he adds. If you have MASH, your doctor may prescribe a drug called resmetirom (Rezdiffra), which is the only FDA-approved treatment for MASH with moderate-to-advanced liver scarring.

  • Talk to your doctor about surgery. “Gastric bypass or a gastric sleeve surgery are often the best long-term solution for maintaining weight loss and resolving the secondary effects of obesity like MASH, diabetes, and high blood pressure,” Ali says. Your doctor may recommend an endobariatric procedure, such as a gastric sleeve or intragastric balloon, which are done with an endoscope and reversible.
  • Avoid alcohol. Although this version of liver disease, MASH, is not primarily attributed to alcohol, drinking — especially more than 21 alcoholic drinks per week for men or 14 for women — can increase your risk.

     It’s especially important to avoid alcohol if you have stage 2 liver fibrosis or more advanced disease.

The Takeaway

  • MASH is a severe form of liver disease that can lead to liver damage if unmanaged. It’s often asymptomatic, so understanding your risk and monitoring your health are important.
  • Obesity is a leading risk factor for MASH, and having other related health conditions, such as high cholesterol, diabetes, or metabolic syndrome, can further increase your risk.
  • If you have obesity, taking steps to lose weight through diet, exercise, medication, or surgery can help lower your risk of MASH. Additionally, staying on top of regular health checkups can help your doctor monitor your liver function and protect your health.

Jonathan G. Stine, MD, MSc, FACP

Medical Reviewer

Jonathan Stine, MD, MSc, FACP, is an associate professor of medicine and public health science at Penn State in State College, Pennsylvania.

As an internationally recognized liver expert with a research and clinical focus on metabolic dysfunction–associated steatotic liver disease (MASLD) and exercise, he has authored more than 100 peer-reviewed papers, including multinational consensus guidelines.

Dr. Stine is the recipient of multiple research grants and awards from the American Association for the Study of Liver Diseases and the American Cancer Society, and has maintained continuous funding from the National Institutes of Health since 2018.

Stine is the MASLD consultant to the American College of Sports Medicine’s “Exercise is Medicine” initiative, and recently co-chaired the International Roundtable on MASLD and Physical Activity for ACSM. He serves as the Fatty Liver Program director as well as the Liver Center Research director for Penn State.

Laurel Leicht

Laurel Leicht

Author

Laurel Leicht has been a writer and editor for nearly two decades. A graduate of the College of William and Mary and the master's program at the Missouri School of Journalism, she covers a wide range of health and fitness topics, including breast cancer, various chronic conditions, mental health, and cardiovascular health.

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Health Risks of Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. May 2023.
  2. Metabolic Dysfunction-Associated Steatohepatitis. Cleveland Clinic. May 3, 2022.
  3. Yanai H et al. Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association With Atherosclerosis and Cardiovascular Disease, and Treatments . International Journal of Molecular Sciences. October 23, 2023.
  4. Obesity, MASLD & MASH [PDF]. American Liver Foundation. 2024.
  5. NASH Causes & Risk Factors. American Liver Foundation. January 18, 2024.
  6. Health Risks of Overweight & Obesity. National Institute of Diabetes and Digestive and Kidney Diseases. May 2023.
  7. Physical Activity and Your Weight and Health. Centers for Disease Control and Prevention. December 27, 2023.
  8. Stine JG et al. Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine. Medicine & Science in Sports & Exercise. September 2023.
  9. FDA Approves First Treatment for Patients With Liver Scarring Due to Fatty Liver Disease. U.S. Food & Drug Administration. March 14, 2024.
  10. Chalasani N et al. The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the American Association for the Study of Liver Diseases [PDF]. Hepatology. January 2018.
  11. Rinella ME et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. May 2023.